Memphis Pharmaceuticals results, Q4 2024
Net profit, assets, equity and cash flow for Q4 2024, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit191 millionEGP · +111.7% vs the same period a year earlier
Total assets1.22 billionEGP · +54.9% vs the same period a year earlier
Shareholders' equity149 millionEGP · +42.0% vs the same period a year earlier
Operating cash flow183 millionEGP · +216.2% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q4 2024 was about 191 million EGP, up +111.7% from 90.44 million EGP in Q4 2023.
- Total assets at the end of Q4 2024 were about 1.22 billion EGP, and shareholders' equity about 149 million EGP.
- Operating cash flow for Q4 2024 was positive at 183 million EGP.
Key lines against the same period a year earlier
This periodQ4 2023Change
Net profit191 million90.44 million+111.7%
Gross profit309 million217 million+42.3%
Total assets1.22 billion786 million+54.9%
Total liabilities1.07 billion681 million+56.9%
Shareholders' equity149 million105 million+42.0%
Total liabilities and equity1.22 billion786 million+54.9%
Operating cash flow183 million57.94 million+216.2%
Investing cash flow30.59 million-582 thousand+5359.4%
Financing cash flow163 million-294 million+155.2%
Net change in cash376 million59.7 million+530.4%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy